Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement

1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)

(2020) N. Gaspar et al.   ANNALS OF ONCOLOGY

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children’s Oncology Group Phase I Consortium Trial.

(2017) J. L. Glade Bender et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone

(2016) E. Palmerini et al.   BMC CANCER

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

(2016) Neyssa M Marina et al.   LANCET ONCOLOGY

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

(2014) A B Suttle et al.   BRITISH JOURNAL OF CANCER

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003

(2012) E. Fox et al.   ONCOLOGIST

Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data

(2012) Tom Treasure et al.   BMJ Open

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

(2011) G. Grignani et al.   ANNALS OF ONCOLOGY

Pazopanib: Clinical development of a potent anti-angiogenic drug

(2010) Fabio A.B. Schutz et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma

(2009) Ayesha Abdeen et al.   CANCER

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH